BioPharmSignal logoBioPharmSignal

Biotech News

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Disc Medicine (IRON)Disc MedicineClinical readout

The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decision Bitopertin, an oral glycine transporter 1 (GlyT1) inhibitor, is being evaluated in the Phase 3 APOLLO clinical trial, with

Related news

IRONDisc Medicine2026-03-26 20:30 EST

Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria

IRONDisc Medicine2026-06-02 12:00 EST

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

RCKTRocket Pharmaceuticals2026-08-03 11:00 EST

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

APVOAptevo Therapeutics2026-05-06 12:05 EST

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

ZNTLZentalis2026-01-06 13:00 EST

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

APVOAptevo Therapeutics2026-05-13 12:05 EST

Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

RIGLRigel Pharmaceuticals2026-03-31 12:05 EST

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

APTOAptose Biosciences, Inc.2025-11-03 14:00 EST

Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

APTOAptose Biosciences, Inc.2026-06-15 11:30 EST

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation

SNDXSyndax Pharmaceuticals2026-06-11 11:03 EST

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

View all latest news

Disc Medicine

Hematology Drug Development Disc Medicine develops therapies for serious hematologic diseases by targeting pathways involved in heme biosynthesis and iron regulation. Its portfolio addresses both rare red-blood-cell disorders and anemia associated with chronic disease. Bitopertin in EPP Bitopertin is being evaluated in the Phase 3 APOLLO...

Recent company news

IRONDisc Medicine2026-07-30 12:30 EST

Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update

IRONDisc Medicine2026-06-12 12:30 EST

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

IRONDisc Medicine2026-06-09 12:30 EST

Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria

IRONDisc Medicine2026-06-02 12:00 EST

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

IRONDisc Medicine2026-06-01 12:30 EST

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Stock data

Close
77.44 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States